Ochratoxin A

from Petromyces albertensis, ≥98% (HPLC)

Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
Beilstein/REAXYS Number:
MDL number:
PubChem Substance ID:

Quality Level

biological source

Petromyces albertensis


≥98% (HPLC)




Benzene, free


ethanol: soluble

Mode of action

enzyme | inhibits
protein synthesis | interferes

storage temp.


SMILES string




InChI key


Looking for similar products? Visit Product Comparison Guide


Ochratoxin A has been used as a mycotoxin:
  • to test its effect on metabolism and hypoxia in human embryonic kidney (HEK293) cells
  • to test its cytotoxic effects in bovine mammary epithelial cells
  • as a standard for gamma radiation studies with food products and in cytotoxic studies using Hep G2 cells


1, 5, 25 mg in glass bottle

Biochem/physiol Actions

Ochratoxin A (OTA), a renal toxin, is produced majorly by Aspergillus and Penicillium fungal species. It is immunotoxic, teratogenic myelotoxic, and mutagenic. It effectively interrupts the intestinal barrier functions. OTA displays a long elimination half-life and stimulates the major inflammatory cytokines release.
Ochratoxin A is a mycotoxin found in food that is nephrotoxic and carcinogenic in the kidney and induces differentiation in cloned renal cell lines. Increases endoplasmic reticulum ATP-dependent Ca2+ pump activity.


Skull and crossbonesHealth hazard

Signal Word


Hazard Statements

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


UN 3462 6.1 / PGII

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
X Chong et al.
Biochemical pharmacology, 44(7), 1401-1409 (1992-10-06)
A disruption of calcium homeostasis, leading to a sustained increase in cytosolic calcium levels, has been associated with cytotoxicity in response to a variety of agents in different cell types. We have observed that administration of a single high dose...
M Gekle et al.
Toxicology and applied pharmacology, 152(1), 282-291 (1998-10-17)
Ochratoxin A (OTA) is a ubiquitous fungal metabolite with predominant nephrotoxic action. OTA impairs postproximal renal electrolyte handling and increases the incidence of renal adenoma and carcinoma. Furthermore, it is supposed to be involved in the pathogenesis of different forms...
G Dirheimer et al.
IARC scientific publications, 115(115), 171-186 (1991-01-01)
Ochratoxin A has a number of toxic effects in mammals, the most notable of which is nephrotoxicity. It is also immunosuppressive, teratogenic and carcinogenic. The biochemical and molecular aspects of its action were first studied in bacteria. The appearance of...
C E Groves et al.
Journal of the American Society of Nephrology : JASN, 10(1), 13-20 (1999-01-16)
Primary cultures of rabbit renal proximal tubule cells grown under improved culture conditions were used to study the transepithelial transport of the nephrotoxic mycotoxin ochratoxin A. The basal-to-apical transepithelial flux, i.e., secretion, of this fluorescence organic acid was measured in...
H Schramek et al.
The Journal of pharmacology and experimental therapeutics, 283(3), 1460-1468 (1998-02-12)
The kidneys represent one of the main targets of ochratoxin A (OTA), a secondary fungal metabolite that is produced by certain species of Aspergillus and Penicillium. OTA has the ability to disturb Madin-Darby canine kidney (MDCK) cell pH homeostasis, leading...
DNA damage and repair mechanism is vital for maintaining DNA integrity. Damage to cellular DNA is involved in mutagenesis, the development of cancer among others.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.